Dr. Andrew Pepper completed his PhD at the University of Western Ontario where he became interested in islet transplantation and beta-cell biology. Post-doctoral research in Dr. James Shapiro’s Laboratory at the University of Alberta forged his passion for translational therapies for the treatment of type 1 diabetes (T1D).
Dr. Pepper is currently an Assistant Professor in the Department of Surgery at the University of Alberta. His group is interested in understanding the underlying mechanisms that govern pancreatic beta-cell survival and function in the context of islet transplantation and T1D onset. Elucidating the relevant cell death pathways, which contribute to islet graft dysfunction, has the potential to promote long-term beta-cell transplant survival and aid in our understanding of the causation of T1D. His laboratory is optimistic that cellular replacement therapies will become the mainstay treatment for a broader spectrum of T1D patients through developing innovative ‘islet-friendly’ transplant modalities and by mitigating beta-cell death.
12:00 - 14:00
|Lunch Workshop: Co-Sponsored by JDRF/Novo Nordisk — Immunoisolation Devices Versus Non Immunoisolating Scaffolds: Pros and Cons||Immunoisolation Devices Versus Non Immunoisolating Scaffolds: Pros and Cons|